Download PDF
Thromb Haemost 1999; 81(05): 847-849
DOI: 10.1055/s-0037-1614582
Letters to the Editor
Schattauer GmbH

Lupus Anticoagulant: Influence on the International Normalized Ratio

J. Arnout
1   From the Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
,
J. Vermylen
1   From the Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 30 November 1998

Accepted 02 February 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders.. Ann Intern Med 1990; 112: 682-98.
    CrossrefPubMedGoogle Scholar
  • 2 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome.. N Engl J Med 1995; 332: 993-7.
    CrossrefPubMedGoogle Scholar
  • 3 Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants.. Ann Intern Med 1997; 127: 177-85.
    CrossrefPubMedGoogle Scholar
  • 4 Della Valle P, Crippa L, Safa O, Tomassini L, Pattarini E, Vigano-d’Ange-lo S, Grazia Sabbadini M, d’Angelo A. Potential failure of the InternationalNormalized Ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants.. Ann Méd Interne 1996; 147: S10-S14.
    PubMedGoogle Scholar
  • 5 Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospho-lipid syndrome.. Br J Haematol 1997; 98: 887-92.
    CrossrefPubMedGoogle Scholar
  • 6 Robert A, Le Querrec A, Delahousse B, Caron C, Houbouyan L, Boutière B, Horrellou MH, Reber G, Sié P. Control of anticoagulation in patients with the antiphospholipid syndrome. Influence of the lupus anticoagulant on International Normalized Ratio.. Thromb Haemost 1998; 80: 99-103.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Arnout J., Vanrusselt M., Huybrechts E., Vermylen J. Optimisation of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br. J.. Haematol. 1994; 87: 94-9.
    CrossrefPubMedGoogle Scholar
  • 8 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta-2-glycoprotein I complexes on phospholipid surfaces.. Thromb Haemost 1998; 79: 79-86.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J.. Monoclonal antibodies against human prothrombin with lupus anticoagulant activity: mechanism of action.. Manuscript in preparation.
    PubMedGoogle Scholar
  • 10 Horbach DA, van Oort E, Derksen RHWM, de Groot PhG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity. Discrimination between functional and non-functional anti-prothrombin antibodies.. Thromb Haemost 1998; 79: 790-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring oral anticoagulant therapy in patients with lupus anticoagulants.. Br J Haematol 1998; 101: 390-1. (letter)
    PubMedGoogle Scholar